Correction
Accepted on 17 Apr 2026
Correction: Elevated IL-17A Level Is Associated with Poor Overall Survival Following Immune Checkpoint Inhibitors Combined with Targeted Therapy in Hepatocellular Carcinoma with Hyperbilirubinemia
in Cancer Immunity and Immunotherapy